Skip to main content
Premium Trial:

Request an Annual Quote

IsoPlexis Inks Distribution Deal With BioStream for Japan

NEW YORK – IsoPlexis said today that it has entered an exclusive agreement with BioStream to distribute its single-cell protein analysis products in Japan.

The Branford, Connecticut-based firm's IsoCode and IsoLight products enable highly multiplexed protein measurements at the single-cell level and have seen uptake in several research areas, particularly in cancer immunotherapy.

"We are very excited to partner with BioStream, a world class distributor of life science systems and technology in Japan," IsoPlexis CEO Sean Mackay said in a statement. "Our single-cell proteomics platform provides a wide range of applications across development and biomarker discovery in cancer immunotherapy, and we look forward to our systems generating impactful data at leading Japanese pharmaceutical companies, research laboratories, and academic institutions."

"Cancer research has grown rapidly in Japan. We are very excited to be the exclusive distributor for IsoPlexis in Japan," said BioStream President Takeshi Iwabuchi. "With IsoPlexis' single-cell proteomic analysis platform, IsoLight and IsoCode Chip, we will accelerate therapeutics research and provide a unique single-cell solution to Japan's bio research market."

Financial and other terms of the agreement were not disclosed.